INTEGRA Biosciences offers liquid handling solutions and magnetic modules to streamline every stage of NGS sample preparation ...

Results of a study led by the Vall d'Hebron Institute of Oncology (VHIO) support the feasibility of using RAD51 testing to ...

Next-generation sequencing, proteomics analysis, and circulating tumor DNA demonstrate how precision medicine advances ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

Regarding cancer treatment facilities in Chattogram, Dr Sazzad said radiotherapy, brachytherapy, and chemotherapy are ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

From being a promising yet underexplored approach in the 1990s, mRNA therapeutics have evolved dramatically. The discovery of ...

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of ...

Sequins, a newly-funded start-up in the next generation sequencing (NGS) ecosystem, announced today the availability of their first commercial products – the Sequins Metagenomics Core Control and ...